Navigation Links
Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
Date:3/8/2013

d.com for more information.

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, any of the Janssen Pharmaceutical Companies and/or Johnson & Johnson.  Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies.  A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.  Neither Janssen Research & Development nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.

Media contacts:
'/>"/>

SOURCE Janssen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
10. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
11. Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... AARP Foundation today announced it has established a ... severe cold weather that has gripped much of the nation. ... need; so to support these emergency relief efforts AARP and ... could mean up to $500,000 in aid. The matching program ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Inc. (Nasdaq: MYL ) and Pfizer Inc. (NYSE: ... a Pfizer subsidiary, has entered into a settlement agreement with ... abbreviated new drug application (ANDA) for a generic epinephrine auto-injector. ... Teva may launch a generic epinephrine auto-injector covered by its ...
... 2012 Shire plc (LSE: SHP, NASDAQ: ... for the three months to March 31, 2012. ... $1,172 Total revenues million +21% Non GAAP operating income $362 ... GAAP diluted earnings per ADS $1.48 +20% US GAAP diluted ...
Cached Medicine Technology:Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva 2Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 2Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 3Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 4Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 5Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 6Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 7Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 8Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 9Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 10Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 11Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 12Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 13Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 14Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 15Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 16Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 17Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 18Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 19Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 20Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 21Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 22Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 23Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 24Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 25
(Date:7/9/2014)... printing on prescription labels handed out by pharmacists ... in taking medication, according to new research by ... Institute for the Blind)., The study, published recently ... that labels on prescription medications dispensed by pharmacies ... legibility. , By simply following recommended guidelines for ...
(Date:7/9/2014)... A study published in the scientific journal ... Bonin, two researchers at Universit Laval, reveals that it ... method that involves rekindling pain so that it can ... means to alleviate chronic pain. , The researchers from ... universitaire en sant mentale de Qubec (IUSMQ) were inspired ...
(Date:7/8/2014)... similar longevity and cardiovascular health as other healthy mature ... American Journal of Transplantation . The findings may ... the transplant professionals caring for them. , Over the ... 55 years and older has become more common. Given ... disease, the removal of a kidney could make older ...
(Date:7/8/2014)... from Plymouth, UK, and Sydney, Australia, have today (Wednesday ... ACEmobile - a free-to-use app to support the assessment ... first of its kind; an iPad-based tool that supports ... the whole process, meaning more members of the clinical ... assessment. Designed by clinicians for clinicians, ACEmobile also collects ...
(Date:7/8/2014)... a biomarker that could give expecting mothers and their ... that a pregnant woman may develop preeclampsia, at least ... Preeclampsia is a cardiovascular disorder generally occurring late in ... immediate and potentially lifelong risks to both mother and ... the urine, and is typically diagnosed in the late ...
Breaking Medicine News(10 mins):Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:Discovery of a new means to erase pain 2Health News:Study finds kidney donation safe for healthy older adults 2Health News:New app widens opportunities for dementia assessments 2Health News:New app widens opportunities for dementia assessments 3Health News:UI researchers find early predictor for preeclampsia 2Health News:UI researchers find early predictor for preeclampsia 3
... series feature eight model methods for effective prospect ... has released its first in a series of ... are using prospect research efficiently and with success ... fundraising, includes survey responses from 60 hospitals and ...
... 1 on annual listOAKLAND, Calif., March 5 ... has been recognized by DiversityMBA ... organization was ranked No. 1 in the publication,s fourth ... for Diverse Managers to Work," which will hit newsstands ...
... To Beaver, Star Jerry MathersJACKSON, Miss., March 5 ... will be stopping in Mississippi the week of March ... to help uninsured and financially-struggling Mississippians access information on ... free. With the unemployment rate in Mississippi (7.8 percent) ...
... for low intake of Omega-3 EPA/DHA amongst , childrenHALIFAX, ... the Journal of Nutrition found that most Canadian children ... 78% of the children trialed were not receiving adequate ... , Researchers from the University of Guelph ...
... ANGELES, March 5 With the nation focused on ... recently announced Assembly Bill 562 ( AB ... businesses and consumers that have fallen victim to price ... health care premium costs. It requires insurance companies to ...
... 5 Ascension Insurance, Inc. has announced ... Lauderdale, effective January 16th 2009. The agency specializes in ... (EMI), a member of the Ascension group of companies ... the Ascension group is managed by Ascension Insurance, Inc. ...
Cached Medicine News:Health News:WealthEngine Releases Best Practices Report for Healthcare Fundraising 2Health News:Kaiser Permanente Recognized as Best Place for Diverse Managers 2Health News:Kaiser Permanente Recognized as Best Place for Diverse Managers 3Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 4Health News:North American Children are Omega-3 Deficient and may be at risk for Suboptimal Health 2Health News:North American Children are Omega-3 Deficient and may be at risk for Suboptimal Health 3Health News:North American Children are Omega-3 Deficient and may be at risk for Suboptimal Health 4Health News:New Health Care Legislation Stops 'Opportunistic' Insurance Pricing 2Health News:Ascension Insurance, Inc. Acquires Fort Lauderdale-based Dennis Bartlett Agency 2
Our 2.5v Ophthalmoscope Sets feature high-quality instruments, handles, and cases....
... are standard in all Welch Allyn ... students, the 18335-SDS combines the superior ... the superior illumination of the Halogen ... of the Finnoff Transilluminator, and the ...
Our 2.5v Streak Retinoscope Sets feature instruments with bright light, reliable handles, and convenient cases....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Medicine Products: